Phase III Clinical Trial of STSP-0601 for Injection in Hemophilia Patients

Study Identifier:
STSP-0601-05
ClinicalTrials.gov Identifier:
EudraCT Identifier:
N/A
Sponsor:
Jiangsu BioJeTay Biotechnology Co., Ltd.
Collaborator:
N/A
Study Contact Information:
Recruiting

Study Details

Medical Condition
  • Hemophilia
Study Drug
  • Drug: STSP-0601 for Injection
Date
Mar 2025 - Sep 2026
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 12 - 70 Years years
Requirements Information

Protocol Summary

This study is looking at how safe it is to switch from emicizumab to Mim8, in people with haemophilia A. Mim8 is a new medicine that is used to prevent bleeding episodes in people with haemophilia A. Mim8 works by replacing the function of the missing clotting factor VIII (FVIII). Mim8 will be injected under the skin using a pen-injector either once every week, once every two weeks or once every month. The participants will be trained in using the pen injector. The participants can choose themselves, in collaboration with the study doctor how often they get Mim8 in this study. When the participant will get their first Mim8 injection depends on their current treatment with emicizumab. The participants will get their first Mim8 injection at Visit 2. Participants will have between 6 and 27 Mim8 injections. The total number of injections participants will have depends on their dosing frequency. The study will last for about 6-12 months. While taking part in this study, there are some restrictions about what medicine participant can use. The study doctor will tell the participants more about this. In case the participants experience bleeds, these can be treated with additional haemostatic medicine as agreed with the study doctor. Female participants cannot take part if they are pregnant, breast-feeding or plan to get pregnant during the study period.

Trial Locations

Location
Status
Location
Anhui Provincial Hospital
Hefei, Anhui, China, 230001
Status
Not yet recruiting
Location
Lanzhou University First Hospital
Lanzhou, Gansu, China, 730000
Status
Not yet recruiting
Location
Shenzhen Second People's Hospital
Shenzhen, Guangdong, China, 518000
Status
Not yet recruiting
Location
The First affiliated hospital of Guangxi Medical University
Nanning, Guangxi, China, 530021
Status
Not yet recruiting
Location
North China University of Science and Technology Affiliated Hospital
Tangshan, Hebei, China, 063000
Status
Not yet recruiting
Location
Harbin First Hospital Hematology Tumor Research Center
Harbin, Heilongjiang, China, 150000
Status
Not yet recruiting